Cardiff drops its lead prostate cancer program, sending shares into a tailspin

Cardiff Oncology is joining the league of companies that have decided to scrap their lead programs, leading the company’s stock to take a nose dive on Tuesday.

The company announced that it will no longer fund its clinical trials for prostate cancer and instead will focus its efforts on pancreatic and metastatic colorectal cancer.